A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC).

Trial Profile

A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC).

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Sipuleucel-T (Primary) ; Abiraterone acetate; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms STAMP
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 05 Jun 2018 Results from STRIDE (n = 12) and STAMP (n = 10) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2018 Results of pooled data from STAMP and STRIDE trial, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 21 May 2018 Results presented at the 113th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top